FindTrial
Sign In

Impact of nefazodone on sleep architecture in insomnia

Impact of nefazodone on sleep architecture in insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN84604889
Enrollment
Unknown
Registered
2003-09-12
Start date
2001-10-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and Behavioural Disorders: Insomnia Mental and Behavioural Disorders Insomnia

Interventions

1. Nefazodone 2. Placebo This is a double blind placebo-controlled crossover study to look at the effects of nefazodone on sleep in insomnia. Patients will be given a two week washout from any psych

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 meeting criteria for insomnia (International Classification of Sleep Disorders) and without: use of other psychotropic drugs, allergy to nefazodone, current or past severe mental illness or substance abuse, current depressive illness.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
1. Objective Total Sleep Time 2. Subjective Sleep Quality—

Secondary

MeasureTime frame
All other measures of objective and subjective sleep—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026